Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeri Kim

Showing results (41-50 of 103) with videos related to

Pageof 11
Sort By:
The Journal of Urology|July 29, 2020
The Association of Periprostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active SurveillanceJustin R Gregg, Devaki Shilpa Surasi, Alexandria Childs, et al.
Oncoimmunology|December 15, 2018
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohortQinchuan Wang, Justin R Gregg, Jian Gu, et al.
The Journal of Urology|April 19, 2011
Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatmentsDeborah J del Junco, Erin E Fox, Sharon Cooper, et al.
Urologic Oncology|December 13, 2003
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)Shi-Ming Tu, Randall E Millikan, Lance C Pagliaro, et al.
Bioinformatics (Oxford, England)|February 16, 2019
Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination predictionLei Huang, David Brunell, Clifford Stephan, et al.
Oncotarget|October 31, 2015
Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancerHuakang Tu, Jian Gu, Qing H Meng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapyShi-Ming Tu, Jeri Kim, Lance C Pagliaro, et al.
Clinical Genitourinary Cancer|January 1, 2017
Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without CarboplatinMehmet Asim Bilen, Diana H Cauley, Bradley J Atkinson, et al.
Cancer|July 1, 2024
Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancerJun Gong, Jessica L Janes, Claire Trustram Eve, et al.
Oncology Letters|April 30, 2017
Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancerHuakang Tu, Jian Gu, Qing H Meng, et al.
Pageof 11

Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
The Journal of Urology|July 29, 2020
The Association of Periprostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active SurveillanceJustin R Gregg, Devaki Shilpa Surasi, Alexandria Childs, et al.
Oncoimmunology|December 15, 2018
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohortQinchuan Wang, Justin R Gregg, Jian Gu, et al.
The Journal of Urology|April 19, 2011
Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatmentsDeborah J del Junco, Erin E Fox, Sharon Cooper, et al.
Urologic Oncology|December 13, 2003
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)Shi-Ming Tu, Randall E Millikan, Lance C Pagliaro, et al.
Bioinformatics (Oxford, England)|February 16, 2019
Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination predictionLei Huang, David Brunell, Clifford Stephan, et al.
Oncotarget|October 31, 2015
Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancerHuakang Tu, Jian Gu, Qing H Meng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapyShi-Ming Tu, Jeri Kim, Lance C Pagliaro, et al.
Clinical Genitourinary Cancer|January 1, 2017
Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without CarboplatinMehmet Asim Bilen, Diana H Cauley, Bradley J Atkinson, et al.
Cancer|July 1, 2024
Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancerJun Gong, Jessica L Janes, Claire Trustram Eve, et al.
Oncology Letters|April 30, 2017
Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancerHuakang Tu, Jian Gu, Qing H Meng, et al.
Pageof 11